Cefdinir colon-positioning enteric tablet

Abstract

The invention discloses cefdinir colon-specific enteric-coated tablets, comprising tablet cores and coating layers. The tablet cores are composed of 10-90 wt.% of cefdinir, 2-70 wt.% of diluting auxiliary materials, 1-20 wt.% of disintegrating auxiliary materials, 1-20 wt.% of adhering auxiliary materials and 0.1-5 wt.% of lubricant auxiliary materials. The cefdinir colon-specific enteric-coated tablets can transmit medicament to colons, improve curative effect of colonitis, have low side effect and improve compliance of patients.

Description

technical field [0001] The invention belongs to the field of new medicine technology, and in particular relates to cefdinir colon-localized enteric-coated tablets. For the treatment of colitis. Background technique [0002] Cefdinir (cefdinir) is the third-generation oral cephalosporin developed by Fujisawa Company in Japan. It not only maintains high stability to β-lactamase, but also improves the performance of third-generation cephalosporins such as cefixime. only for G - Bacterial effect is strong, but for G + It has the characteristics of broad antibacterial spectrum, high curative effect and low toxicity. It was first launched in Japan in December 1991 under the product name . In December 1997, it was approved by the FDA to go on the market in the United States under the trade name . It was launched in South Korea in 1999. In 2001, Cefdinir Capsules produced by Tianjin Central Pharmaceutical Co., Ltd. was launched in China. The trade name is Shifu . [0003...

AI Technical Summary

Problems solved by technology

[0005] According to reports by Watanabe et al., in vitro antibacterial experiments have proved that after years of clinical use of cefdinir, its antibacterial activity against major clinical pathogens has not decreased.